SL4903 CAR-T Therapy for r/r MM With Extramedullary Disease
Status:
NOT_YET_RECRUITING
Trial end date:
2028-10-30
Target enrollment:
Participant gender:
Summary
This study is a single-center, single-arm, open-label clinical trial designed to evaluate the safety and efficacy of SL4903 cell therapy in relapsed or refractory multiple myeloma patients with extramedullary disease.
After being screened by the inclusion/exclusion criteria, eligible subjects were administered SL4903 cell therapy.
This study follows the "3+3" dose escalation model, with three dose cohorts (110\^6, 210\^6, and 310\^6 CAR+ cells/kg). A total of 9 to 18 subjects are expected to be enrolled to evaluate the safety and tolerability of SL4903 autologous T-cell injection and determine the maximum tolerated dose (MTD).
Phase:
EARLY_PHASE1
Details
Lead Sponsor:
Institute of Hematology & Blood Diseases Hospital, China